The MDMA therapy’s phase-3 trial has proved to be a successful way of treating severe Post-Traumatic Stress Disorder (PTSD). This therapy achieved high statistical results and a good safety record.
At the end of the MDMA therapy’s Phase-3 trial, 67 percent of participants who got three MDMA therapy sessions didn’t qualify for a PTSD diagnosis while 88 percent experienced a decline in PTSD symptoms.
The study was carried out on 90 patients who suffered from severe PTSD with an average time of 14 years and replicated the outcome of its Phase 2 trials. Patients who had PTSD influenced by events like sexual harm, abuse, accidents were included in the study, and also 84 percent who once had developmental trauma.
While many forms of PTSD therapy involve recalling previous trauma, the unique ability of MDMA to raise compassion and understanding while tamping down fear is likely what enables it to be so effective.Jennifer Mitchell, Ph.D., lead author of the paper
Participants who underwent the MDMA plus manual therapy in the Phase 3 trial of psychedelic-assisted therapy experienced a reduction in symptoms of PTSD when compared to people who took a placebo with therapy.
67 percent of the study group who underwent MDMA therapy didn’t qualify for a PTSD diagnosis after three different treatment sessions. Furthermore, participants who received MDMA-assisted therapy experienced huge reductions in PTSD symptoms relative to placebo with therapy.
90 patients who suffered from severe PTSD were treated in the trial. Participants were randomly picked to get three sessions of either placebo or MDMA. 46 participants underwent MDMA therapy while the rest received a placebo. The efficacy of the treatment depended on the change from baseline in an assessed clinical interview of the severity of PTSD after 18 weeks.